Doer Bio Named to Hangzhou's Unicorn-Bound List for Fourth Consecutive Year Amid IPO Filing
Doer Biologics
Biological Drug Developer
On the afternoon of April 24, 2024, the eighth "All Things Grow" Conference was held in Hangzhou, guided by the Central Committee of the China Democratic建国Party and the China Association for Science and Technology, and jointly organized by the Zhejiang Provincial Committee of the China Democratic建国Party and the China Investment Development Promotion Association. At the conference, the Hangzhou Venture Capital Association, in collaboration with MicroChain, released the "2024 Hangzhou Unicorn & Quasi-Unicorn Enterprise List."Zhejiang Doer Biologics Co., Ltd. Again Honored on Hangzhou Near-Unicorn Enterprise List。
A total of 117 healthcare quasi-unicorn companies were featured on this year's list, with Doer Biologics making its fourth consecutive appearance. Quasi-unicorns refer to companies valued at over $100 million, demonstrating rapid growth, relative scarcity, and the potential to evolve into unicorns within a short period. The continued recognition for four years in a row affirms Doer Biologics' tremendous development potential in the innovative biopharmaceutical field and acknowledges the company’s unwavering commitment to R&D and innovation over the years.
Currently, the company has successfully advanced five innovative drug projects into Phase I clinical trials. In the future, Doer Biologics will continue to focus on researching multi-specific innovative biologics based on multi-domain structures, constantly developing innovative biologics with proprietary intellectual property rights to address unmet clinical needs. Meanwhile, adhering to the rigorous "DOER" scientific spirit, and driven by the corporate vision of contributing to human health through diligent and innovative work, we will devote ourselves to the development of innovative biologic drugs. Through the gradual efforts of our team, we aim to contribute to human health!
About Doer Biologics
Zhejiang Doer Biologics Co., Ltd. was established on April 1, 2014, with a registered capital of 52.12 million yuan. It is a high-tech enterprise under Huadong Medicine (Stock Code: SZ.000963) specializing in the development of innovative biopharmaceuticals. The company's R&D center is located in Hangzhou Medical Port Town. Doer Biologics focuses on developing multi-specific innovative protein drugs based on multi-domain structures to meet unmet clinical needs in areas such as metabolic diseases and cancer. In 2018, it was recognized as a National High-tech Enterprise, and in 2021, it passed the reevaluation for this designation while also being selected as one of Hangzhou's "quasi-unicorn" enterprises.
Doer Biologics, named after Dalton, the atomic mass unit, which is the basic measurement unit for all drugs. Though Dalton represents the smallest unit, it is also the most essential. Inspired by this, Doer Biologics hopes to become a core part of China's innovative biopharmaceutical industry through the team's gradual accumulation of efforts.
For more information about Doer Biologics, please visit the company website: www.doerbio.com or contact the company email bd@doerbio.com.